Form 4: Iteos Therapeutics COO Matthew Call Receives Stock Options and Restricted Stock Units

Matthew Call, Chief Operating Officer of Iteos Therapeutics, acquired 145,000 stock options and 24,000 restricted stock units on March 7, 2025.

Summary

• On March 7, 2025, Matthew Call, the Chief Operating Officer of Iteos Therapeutics, received 24,000 restricted stock units (RSUs) and 145,000 stock options.
• The RSUs vest over four years, with 25% vesting on March 7, 2026, and the remainder vesting equally on an annual basis over the subsequent three years, contingent upon continued service.
• The stock options also vest over four years, with 25% vesting on March 7, 2026, and the rest vesting in equal monthly installments over the following 36 months, also subject to continued service.
• The exercise price for the stock options is $7.05, and they expire on March 7, 2035.
• Following these transactions, Mr. Call directly owns 161,898 shares of common stock and 145,000 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no red flags or negative aspects in the filing.

Positives

• The grant of RSUs and stock options aligns the COO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedules encourage continued service and commitment from the COO.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a commitment to long-term value creation at Iteos Therapeutics.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to align management's interests with shareholder value.
• Vesting schedules, like the four-year schedule described, are typical to ensure long-term commitment from executives.
• Comparing the size of the grant to similar companies and executive roles would provide further context on the competitiveness of the compensation package.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively as it incentivizes management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates